Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Accounts payable	364,900)	303,900)	195,000)	155,139)	87,610)
Product revenue accruals	1,716,400)	1,300,800)	847,400)	781,903)	641,368)
Payroll and benefits	295,000)	246,500)	191,300)	169,387)	159,464)
Research, development and commercial contract costs	265,200)	198,700)	171,600)	136,704)	105,663)
Royalty payable	237,600)	215,000)	200,400)	165,404)	98,578)
Tax related accruals	99,500)	123,300)	211,300)	104,173)	72,293)
Other	41,600)	42,400)	56,600)	47,400)	39,546)
Accrued expenses	2,655,300)	2,126,700)	1,678,600)	1,404,971)	1,116,912)
Milestone payment due to CRISPR	200,000)	—)	—)	—)	—)
Contract liabilities	170,300)	159,600)	171,700)	191,519)	62,332)
Current finance lease liabilities	50,600)	40,800)	46,900)	42,434)	38,794)
Current operating lease liabilities	33,100)	48,600)	33,300)	10,521)	11,504)
Other	73,200)	62,500)	16,500)	72,949)	17,675)
Other current liabilities	527,200)	311,500)	268,400)	317,423)	130,305)
Current liabilities	3,547,400)	2,742,100)	2,142,000)	1,877,533)	1,334,827)
Long-term finance lease liabilities	376,100)	430,800)	509,800)	539,042)	538,576)
Long-term operating lease liabilities	348,600)	379,500)	377,400)	350,463)	84,292)
Tax-related liabilities	681,400)	452,800)	—)	—)	—)
Contingent consideration	77,400)	114,400)	186,500)	189,600)	176,500)
Other	118,900)	118,600)	116,800)	108,355)	99,026)
Other long-term liabilities	877,700)	685,800)	303,300)	297,955)	275,526)
Long-term liabilities	1,602,400)	1,496,100)	1,190,500)	1,187,460)	898,394)
Total liabilities	5,149,800)	4,238,200)	3,332,500)	3,064,993)	2,233,221)
Preferred stock, $0.01 par value; none issued and outstanding	—)	—)	—)	—)	—)
Common stock, $0.01 par value	2,600)	2,600)	2,500)	2,599)	2,589)
Additional paid-in capital	7,449,700)	7,386,500)	6,880,800)	7,894,027)	7,937,606)
Accumulated other comprehensive income (loss)	(14,300)	800)	15,900)	(68,480)	(1,973)
Retained earnings (accumulated deficit)	10,142,400)	6,522,800)	3,200,800)	858,669)	(1,852,978)
Shareholders’ equity	17,580,400)	13,912,700)	10,100,000)	8,686,815)	6,085,244)
Total liabilities and shareholders’ equity	22,730,200)	18,150,900)	13,432,500)	11,751,808)	8,318,465)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Vertex Pharmaceuticals Inc. current liabilities increased from 2021 to 2022 and from 2022 to 2023.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Vertex Pharmaceuticals Inc. long-term liabilities increased from 2021 to 2022 and from 2022 to 2023.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Vertex Pharmaceuticals Inc. total liabilities increased from 2021 to 2022 and from 2022 to 2023.
Shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Vertex Pharmaceuticals Inc. shareholders’ equity increased from 2021 to 2022 and from 2022 to 2023.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Balance Sheet: Liabilities and Stockholders’ Equity